Assessment of health-related quality of life and how it predicts the outcome of pegylated interferon and ribavirin therapy for chronic hepatitis C

Hiroshi Matsushita, Fusao Ikeda, Yoshiaki Iwasaki, Hiroyuki Seki, Shintaro Nanba, Yasuto Takeuchi, Yuki Moritou, Tetsuya Yasunaka, Hideki Ohnishi, Yasuhiro Miyake, Akinobu Takaki, Kazuhiro Nouso, Kazuhide Yamamoto

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Background and Aim: Chronic infection with hepatitis C virus (HCV) decreases health-related quality of life (HRQOL). The present study was planned to investigate the impact of HRQOL of patients with chronic hepatitis C (CHC) on the outcomes of therapy with pegylated interferon and ribavirin (RBV), in addition to IL28B polymorphisms. Methods: The present study enrolled 228 CHC patients and assessed their HRQOLs prospectively with the 36-item short-form health survey. Results: The patients with CHC have lower physical HRQOL status than the general population (P=0.037, the Z-test). The patients with advanced liver diseases exhibited further decreases in HRQOL (P=0.036, Spearman's rank correlation coefficient). The score of total HRQOL was significantly lower in the group with sustained virological response (SVR) to the therapy with pegylated interferon and RBV than the non-SVR group (P=0.031, the Mann-Whitney U-test), with significantly lower scores of mental component and its comprising subscales in the SVR group. Stepwise multivariate logistic regression analysis showed that low HRQOL score ≤400 points was significantly associated with SVR (odds ratio=2.4, P=0.013), independently from high platelet counts, low HCV RNA, favorable single-nucleotide polymorphism type of IL28B, and HCV serotype 2. The patients with low HRQOL score will have significantly less decrease in HRQOL score by 4 weeks of the treatment than those with high HRQOL score at baseline (P=0.0045). Conclusion: HRQOL is one of the significant predictor of the outcomes of therapy with pegylated interferon and RBV independently from IL28B polymorphism.

Original languageEnglish
Pages (from-to)337-343
Number of pages7
JournalJournal of Gastroenterology and Hepatology (Australia)
Volume29
Issue number2
DOIs
Publication statusPublished - Feb 1 2014

Fingerprint

Ribavirin
Chronic Hepatitis C
Interferons
Quality of Life
Hepacivirus
Therapeutics
Nonparametric Statistics
Health Surveys
Platelet Count
Single Nucleotide Polymorphism
Liver Diseases
Logistic Models
Odds Ratio
Regression Analysis
RNA

Keywords

  • HCV
  • Interferon
  • QOL

ASJC Scopus subject areas

  • Gastroenterology
  • Hepatology
  • Medicine(all)

Cite this

Assessment of health-related quality of life and how it predicts the outcome of pegylated interferon and ribavirin therapy for chronic hepatitis C. / Matsushita, Hiroshi; Ikeda, Fusao; Iwasaki, Yoshiaki; Seki, Hiroyuki; Nanba, Shintaro; Takeuchi, Yasuto; Moritou, Yuki; Yasunaka, Tetsuya; Ohnishi, Hideki; Miyake, Yasuhiro; Takaki, Akinobu; Nouso, Kazuhiro; Yamamoto, Kazuhide.

In: Journal of Gastroenterology and Hepatology (Australia), Vol. 29, No. 2, 01.02.2014, p. 337-343.

Research output: Contribution to journalArticle

Matsushita, Hiroshi ; Ikeda, Fusao ; Iwasaki, Yoshiaki ; Seki, Hiroyuki ; Nanba, Shintaro ; Takeuchi, Yasuto ; Moritou, Yuki ; Yasunaka, Tetsuya ; Ohnishi, Hideki ; Miyake, Yasuhiro ; Takaki, Akinobu ; Nouso, Kazuhiro ; Yamamoto, Kazuhide. / Assessment of health-related quality of life and how it predicts the outcome of pegylated interferon and ribavirin therapy for chronic hepatitis C. In: Journal of Gastroenterology and Hepatology (Australia). 2014 ; Vol. 29, No. 2. pp. 337-343.
@article{843c7e55b37941b3952e870a47101855,
title = "Assessment of health-related quality of life and how it predicts the outcome of pegylated interferon and ribavirin therapy for chronic hepatitis C",
abstract = "Background and Aim: Chronic infection with hepatitis C virus (HCV) decreases health-related quality of life (HRQOL). The present study was planned to investigate the impact of HRQOL of patients with chronic hepatitis C (CHC) on the outcomes of therapy with pegylated interferon and ribavirin (RBV), in addition to IL28B polymorphisms. Methods: The present study enrolled 228 CHC patients and assessed their HRQOLs prospectively with the 36-item short-form health survey. Results: The patients with CHC have lower physical HRQOL status than the general population (P=0.037, the Z-test). The patients with advanced liver diseases exhibited further decreases in HRQOL (P=0.036, Spearman's rank correlation coefficient). The score of total HRQOL was significantly lower in the group with sustained virological response (SVR) to the therapy with pegylated interferon and RBV than the non-SVR group (P=0.031, the Mann-Whitney U-test), with significantly lower scores of mental component and its comprising subscales in the SVR group. Stepwise multivariate logistic regression analysis showed that low HRQOL score ≤400 points was significantly associated with SVR (odds ratio=2.4, P=0.013), independently from high platelet counts, low HCV RNA, favorable single-nucleotide polymorphism type of IL28B, and HCV serotype 2. The patients with low HRQOL score will have significantly less decrease in HRQOL score by 4 weeks of the treatment than those with high HRQOL score at baseline (P=0.0045). Conclusion: HRQOL is one of the significant predictor of the outcomes of therapy with pegylated interferon and RBV independently from IL28B polymorphism.",
keywords = "HCV, Interferon, QOL",
author = "Hiroshi Matsushita and Fusao Ikeda and Yoshiaki Iwasaki and Hiroyuki Seki and Shintaro Nanba and Yasuto Takeuchi and Yuki Moritou and Tetsuya Yasunaka and Hideki Ohnishi and Yasuhiro Miyake and Akinobu Takaki and Kazuhiro Nouso and Kazuhide Yamamoto",
year = "2014",
month = "2",
day = "1",
doi = "10.1111/jgh.12337",
language = "English",
volume = "29",
pages = "337--343",
journal = "Journal of Gastroenterology and Hepatology (Australia)",
issn = "0815-9319",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Assessment of health-related quality of life and how it predicts the outcome of pegylated interferon and ribavirin therapy for chronic hepatitis C

AU - Matsushita, Hiroshi

AU - Ikeda, Fusao

AU - Iwasaki, Yoshiaki

AU - Seki, Hiroyuki

AU - Nanba, Shintaro

AU - Takeuchi, Yasuto

AU - Moritou, Yuki

AU - Yasunaka, Tetsuya

AU - Ohnishi, Hideki

AU - Miyake, Yasuhiro

AU - Takaki, Akinobu

AU - Nouso, Kazuhiro

AU - Yamamoto, Kazuhide

PY - 2014/2/1

Y1 - 2014/2/1

N2 - Background and Aim: Chronic infection with hepatitis C virus (HCV) decreases health-related quality of life (HRQOL). The present study was planned to investigate the impact of HRQOL of patients with chronic hepatitis C (CHC) on the outcomes of therapy with pegylated interferon and ribavirin (RBV), in addition to IL28B polymorphisms. Methods: The present study enrolled 228 CHC patients and assessed their HRQOLs prospectively with the 36-item short-form health survey. Results: The patients with CHC have lower physical HRQOL status than the general population (P=0.037, the Z-test). The patients with advanced liver diseases exhibited further decreases in HRQOL (P=0.036, Spearman's rank correlation coefficient). The score of total HRQOL was significantly lower in the group with sustained virological response (SVR) to the therapy with pegylated interferon and RBV than the non-SVR group (P=0.031, the Mann-Whitney U-test), with significantly lower scores of mental component and its comprising subscales in the SVR group. Stepwise multivariate logistic regression analysis showed that low HRQOL score ≤400 points was significantly associated with SVR (odds ratio=2.4, P=0.013), independently from high platelet counts, low HCV RNA, favorable single-nucleotide polymorphism type of IL28B, and HCV serotype 2. The patients with low HRQOL score will have significantly less decrease in HRQOL score by 4 weeks of the treatment than those with high HRQOL score at baseline (P=0.0045). Conclusion: HRQOL is one of the significant predictor of the outcomes of therapy with pegylated interferon and RBV independently from IL28B polymorphism.

AB - Background and Aim: Chronic infection with hepatitis C virus (HCV) decreases health-related quality of life (HRQOL). The present study was planned to investigate the impact of HRQOL of patients with chronic hepatitis C (CHC) on the outcomes of therapy with pegylated interferon and ribavirin (RBV), in addition to IL28B polymorphisms. Methods: The present study enrolled 228 CHC patients and assessed their HRQOLs prospectively with the 36-item short-form health survey. Results: The patients with CHC have lower physical HRQOL status than the general population (P=0.037, the Z-test). The patients with advanced liver diseases exhibited further decreases in HRQOL (P=0.036, Spearman's rank correlation coefficient). The score of total HRQOL was significantly lower in the group with sustained virological response (SVR) to the therapy with pegylated interferon and RBV than the non-SVR group (P=0.031, the Mann-Whitney U-test), with significantly lower scores of mental component and its comprising subscales in the SVR group. Stepwise multivariate logistic regression analysis showed that low HRQOL score ≤400 points was significantly associated with SVR (odds ratio=2.4, P=0.013), independently from high platelet counts, low HCV RNA, favorable single-nucleotide polymorphism type of IL28B, and HCV serotype 2. The patients with low HRQOL score will have significantly less decrease in HRQOL score by 4 weeks of the treatment than those with high HRQOL score at baseline (P=0.0045). Conclusion: HRQOL is one of the significant predictor of the outcomes of therapy with pegylated interferon and RBV independently from IL28B polymorphism.

KW - HCV

KW - Interferon

KW - QOL

UR - http://www.scopus.com/inward/record.url?scp=84907290716&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907290716&partnerID=8YFLogxK

U2 - 10.1111/jgh.12337

DO - 10.1111/jgh.12337

M3 - Article

C2 - 23869873

AN - SCOPUS:84907290716

VL - 29

SP - 337

EP - 343

JO - Journal of Gastroenterology and Hepatology (Australia)

JF - Journal of Gastroenterology and Hepatology (Australia)

SN - 0815-9319

IS - 2

ER -